Exelixis (EXEL) – Globe Newswire
-
Anal Cancer Treatment Market Expected to Reach $1.63 Billion by 2030 as Latest Clinical Studies Focus on New Therapies
-
Exelixis and Ipsen Announce Positive Results from Phase 3 CONTACT-02 Pivotal Trial Evaluating Cabozantinib in Combination with Atezolizumab in Metastatic Castration-Resistant Prostate Cancer
-
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
-
Phathom Pharmaceuticals Appoints Frank Karbe to its Board of Directors
-
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
-
XWPharma Names Michael M. Morrissey, PhD to Board of Directors
Back to EXEL Stock Lookup